Severity of SARS-CoV-2 infection in a hospital population: a clinical comparison across age groups.
COVID-19
MIS-C
Outcome
Paediatric population
SARS-CoV-2 infection
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
08 Oct 2023
08 Oct 2023
Historique:
received:
25
02
2023
accepted:
22
06
2023
medline:
30
10
2023
pubmed:
9
10
2023
entrez:
8
10
2023
Statut:
epublish
Résumé
Children tend to have milder forms of COVID-19 than adults, however post-acute complications have been observed also in the paediatric population. In this study, we compared COVID-19-related outcomes and long-term complications between paediatric and adult patients infected by SARS-CoV-2. The study is based on individuals enrolled from October 2020 to June 2021 in the DECO COVID-19 multicentre prospective study supported by the Italian Ministry of Health (COVID-2020-12371781). We included individuals with RT-PCR -confirmed SARS-CoV-2 infection, who were evaluated in the emergency department and/or admitted to COVID-dedicated wards. The severity of SARS-CoV-2 infection was compared across age groups (children/adolescents aged < 18 years, young/middle-aged adults aged 18-64 years and older individuals) through the relative risk (RR) of severe COVID-19. Severity was defined by: 1) hospitalization due to COVID-19 and/or 2) need or supplemental oxygen therapy. RR and corresponding 95% confidence intervals were estimated using log-binomial models. The study included 154 individuals, 84 (54.5%) children/adolescents, 50 (32.5%) young/middle-aged adults and 20 (13%) older adults. Compared to young/middle-aged adults the risk of hospitalization was lower among paediatric patients (RR: 0.49, 95% CI: 0.32-0.75) and higher among older adults (RR: 1.52, 95% CI: 1.12-2.06). The RR of supplemental oxygen was 0.12 (95% CI: 0.05-0.30) among children/adolescents and 1.46 (95% CI: 0.97-2.19) among older adults. Three children developed multisystem inflammatory syndrome (MIS-C), none was admitted to intensive care unit or reported post-acute Covid-19 complications. Our study confirms that COVID-19 is less severe in children. MIS-C is a rare yet severe complication of SARS-CoV-2 infection in children and its risk factors are presently unknown.
Sections du résumé
BACKGROUND
BACKGROUND
Children tend to have milder forms of COVID-19 than adults, however post-acute complications have been observed also in the paediatric population. In this study, we compared COVID-19-related outcomes and long-term complications between paediatric and adult patients infected by SARS-CoV-2.
METHODS
METHODS
The study is based on individuals enrolled from October 2020 to June 2021 in the DECO COVID-19 multicentre prospective study supported by the Italian Ministry of Health (COVID-2020-12371781). We included individuals with RT-PCR -confirmed SARS-CoV-2 infection, who were evaluated in the emergency department and/or admitted to COVID-dedicated wards. The severity of SARS-CoV-2 infection was compared across age groups (children/adolescents aged < 18 years, young/middle-aged adults aged 18-64 years and older individuals) through the relative risk (RR) of severe COVID-19. Severity was defined by: 1) hospitalization due to COVID-19 and/or 2) need or supplemental oxygen therapy. RR and corresponding 95% confidence intervals were estimated using log-binomial models.
RESULTS
RESULTS
The study included 154 individuals, 84 (54.5%) children/adolescents, 50 (32.5%) young/middle-aged adults and 20 (13%) older adults. Compared to young/middle-aged adults the risk of hospitalization was lower among paediatric patients (RR: 0.49, 95% CI: 0.32-0.75) and higher among older adults (RR: 1.52, 95% CI: 1.12-2.06). The RR of supplemental oxygen was 0.12 (95% CI: 0.05-0.30) among children/adolescents and 1.46 (95% CI: 0.97-2.19) among older adults. Three children developed multisystem inflammatory syndrome (MIS-C), none was admitted to intensive care unit or reported post-acute Covid-19 complications.
CONCLUSIONS
CONCLUSIONS
Our study confirms that COVID-19 is less severe in children. MIS-C is a rare yet severe complication of SARS-CoV-2 infection in children and its risk factors are presently unknown.
Identifiants
pubmed: 37807040
doi: 10.1186/s13052-023-01485-w
pii: 10.1186/s13052-023-01485-w
pmc: PMC10561461
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Subventions
Organisme : Ministero della Salute
ID : COVID-2020-12371781
Informations de copyright
© 2023. The Author(s).
Références
Rev Paul Pediatr. 2022 Apr 04;40:e2021046
pubmed: 35442269
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Pediatr Pulmonol. 2021 Aug;56(8):2495-2502
pubmed: 34102037
BMJ Open. 2021 Dec 7;11(12):e049752
pubmed: 34876424
Lancet Respir Med. 2021 Feb;9(2):129
pubmed: 33453162
Cochrane Database Syst Rev. 2022 May 20;5:CD013665
pubmed: 35593186
J Neurosurg Anesthesiol. 2022 Jan 1;34(1):141-147
pubmed: 34870638
Hematol Oncol Clin North Am. 2015 Oct;29(5):927-41
pubmed: 26461152
BMJ Open. 2021 Jan 11;11(1):e044640
pubmed: 33431495
Biomed Environ Sci. 2020 Dec 20;33(12):906-915
pubmed: 33472730
Arch Med Res. 2022 Jan;53(1):1-8
pubmed: 34311990
MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1249-1254
pubmed: 34499628
Front Public Health. 2021 Sep 09;9:738423
pubmed: 34568267
Pediatr Ann. 2021 Jul;50(7):e277-e281
pubmed: 34264800
J Med Virol. 2021 Feb;93(2):1057-1069
pubmed: 32761898
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Int J Infect Dis. 2021 Feb;103:246-256
pubmed: 33227520
Paediatr Respir Rev. 2021 Jun;38:51-57
pubmed: 32891582
Int J Pediatr. 2020 Nov 18;2020:9680905
pubmed: 33299428
Pediatr Res. 2021 Mar;89(4):733-737
pubmed: 32555539
Am J Emerg Med. 2022 Sep;59:133-140
pubmed: 35849960
World J Pediatr. 2022 Mar;18(3):149-159
pubmed: 35118594
Pediatr Infect Dis J. 2021 Dec 1;40(12):e482-e487
pubmed: 34870392
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Eur J Pediatr. 2021 Mar;180(3):689-697
pubmed: 32914200
Pediatr Pulmonol. 2021 Jun;56(6):1342-1356
pubmed: 33721405
JAMA Netw Open. 2021 Jun 1;4(6):e2116420
pubmed: 34110391
Eur J Pediatr. 2021 Jul;180(7):2019-2034
pubmed: 33599835
Pediatr Infect Dis J. 2020 Jun;39(6):469-477
pubmed: 32398569
Arthritis Rheumatol. 2021 Apr;73(4):e13-e29
pubmed: 33277976
J Clin Virol. 2021 Feb;135:104715
pubmed: 33348220
PLoS One. 2021 Mar 4;16(3):e0247461
pubmed: 33661992
J Cyst Fibros. 2021 Jan;20(1):25-30
pubmed: 33309057
Life (Basel). 2022 Feb 14;12(2):
pubmed: 35207572
Diabetes Care. 2021 Jun;44(6):1281-1290
pubmed: 33858854
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
Sci Rep. 2022 Jun 23;12(1):9950
pubmed: 35739136